Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived … – GlobeNewswire (press release)
|
Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived …
GlobeNewswire (press release) SAN DIEGO, Dec. 06, 2017 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today a … |
